Literature DB >> 29221806

Characterization of Gene Alterations following Editing of the β-Globin Gene Locus in Hematopoietic Stem/Progenitor Cells.

Joseph Long1, Megan D Hoban2, Aaron R Cooper3, Michael L Kaufman2, Caroline Y Kuo4, Beatriz Campo-Fernandez2, Dianne Lumaquin2, Roger P Hollis2, Xiaoyan Wang5, Donald B Kohn6, Zulema Romero7.   

Abstract

The use of engineered nucleases combined with a homologous DNA donor template can result in targeted gene correction of the sickle cell disease mutation in hematopoietic stem and progenitor cells. However, because of the high homology between the adjacent human β- and δ-globin genes, off-target cleavage is observed at δ-globin when using some endonucleases targeted to the sickle mutation in β-globin. Introduction of multiple double-stranded breaks by endonucleases has the potential to induce intergenic alterations. Using a novel droplet digital PCR assay and high-throughput sequencing, we characterized the frequency of rearrangements between the β- and δ-globin paralogs when delivering these nucleases. Pooled CD34+ cells and colony-forming units from sickle bone marrow were treated with nuclease only or including a donor template and then analyzed for potential gene rearrangements. It was observed that, in pooled CD34+ cells and colony-forming units, the intergenic β-δ-globin deletion was the most frequent rearrangement, followed by inversion of the intergenic fragment, with the inter-chromosomal translocation as the least frequent. No rearrangements were observed when endonuclease activity was restricted to on-target β-globin cleavage. These findings demonstrate the need to develop site-specific endonucleases with high specificity to avoid unwanted gene alterations.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chromosomal rearrangement; endonucleases; off-target

Mesh:

Substances:

Year:  2017        PMID: 29221806      PMCID: PMC5835144          DOI: 10.1016/j.ymthe.2017.11.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases.

Authors:  Hyung Joo Lee; Jiyeon Kweon; Eunji Kim; Seokjoong Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2011-12-19       Impact factor: 9.043

Review 2.  Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.

Authors:  Shengdar Q Tsai; J Keith Joung
Journal:  Nat Rev Genet       Date:  2016-05       Impact factor: 53.242

3.  Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells.

Authors:  C S Osborne; P Pasceri; R Singal; T Sukonnik; G D Ginder; J Ellis
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

5.  miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction.

Authors:  Swaroopa Guda; Christian Brendel; Raffaele Renella; Peng Du; Daniel E Bauer; Matthew C Canver; Jennifer K Grenier; Andrew W Grimson; Sophia C Kamran; James Thornton; Helen de Boer; David E Root; Michael D Milsom; Stuart H Orkin; Richard I Gregory; David A Williams
Journal:  Mol Ther       Date:  2015-06-17       Impact factor: 11.454

6.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

7.  Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases.

Authors:  Carmen F Bjurström; Michelle Mojadidi; John Phillips; Caroline Kuo; Stephen Lai; Georgia R Lill; Aaron Cooper; Michael Kaufman; Fabrizia Urbinati; Xiaoyan Wang; Roger P Hollis; Donald B Kohn
Journal:  Mol Ther Nucleic Acids       Date:  2016       Impact factor: 8.886

8.  Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus.

Authors:  Anne Bothmer; Tanushree Phadke; Luis A Barrera; Carrie M Margulies; Christina S Lee; Frank Buquicchio; Sean Moss; Hayat S Abdulkerim; William Selleck; Hariharan Jayaram; Vic E Myer; Cecilia Cotta-Ramusino
Journal:  Nat Commun       Date:  2017-01-09       Impact factor: 14.919

Review 9.  Beta-thalassemia.

Authors:  Antonio Cao; Renzo Galanello
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

10.  Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing.

Authors:  Jiazhi Hu; Robin M Meyers; Junchao Dong; Rohit A Panchakshari; Frederick W Alt; Richard L Frock
Journal:  Nat Protoc       Date:  2016-03-31       Impact factor: 13.491

View more
  10 in total

1.  Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.

Authors:  Zulema Romero; Anastasia Lomova; Suzanne Said; Alexandra Miggelbrink; Caroline Y Kuo; Beatriz Campo-Fernandez; Megan D Hoban; Katelyn E Masiuk; Danielle N Clark; Joseph Long; Julie M Sanchez; Miriam Velez; Eric Miyahira; Ruixue Zhang; Devin Brown; Xiaoyan Wang; Yerbol Z Kurmangaliyev; Roger P Hollis; Donald B Kohn
Journal:  Mol Ther       Date:  2019-05-24       Impact factor: 11.454

2.  High level of fetal-globin reactivation by designed transcriptional activator-like effector.

Authors:  Jun Zhan; Maria Johnson Irudayam; Yukio Nakamura; Ryo Kurita; Arthur W Nienhuis
Journal:  Blood Adv       Date:  2020-02-25

Review 3.  Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.

Authors:  Paula Germino-Watnick; Malikiya Hinds; Anh Le; Rebecca Chu; Xiong Liu; Naoya Uchida
Journal:  Cells       Date:  2022-06-04       Impact factor: 7.666

4.  High-level correction of the sickle mutation is amplified in vivo during erythroid differentiation.

Authors:  Wendy Magis; Mark A DeWitt; Stacia K Wyman; Jonathan T Vu; Seok-Jin Heo; Shirley J Shao; Finn Hennig; Zulema G Romero; Beatriz Campo-Fernandez; Suzanne Said; Matthew S McNeill; Garrett R Rettig; Yongming Sun; Yu Wang; Mark A Behlke; Donald B Kohn; Dario Boffelli; Mark C Walters; Jacob E Corn; David I K Martin
Journal:  iScience       Date:  2022-05-10

5.  Impact of a grant program to spur advances in sickle cell disease research.

Authors:  Sindy N Escobar Alvarez; Elizabeth R Myers
Journal:  Blood Adv       Date:  2021-10-12

6.  CRISPR-Directed Therapeutic Correction at the NCF1 Locus Is Challenged by Frequent Incidence of Chromosomal Deletions.

Authors:  Dominik Wrona; Oleksandr Pastukhov; Robert S Pritchard; Federica Raimondi; Joëlle Tchinda; Martin Jinek; Ulrich Siler; Janine Reichenbach
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-25       Impact factor: 6.698

7.  Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease.

Authors:  Naoya Uchida; Claire M Drysdale; Tina Nassehi; Jackson Gamer; Morgan Yapundich; Julia DiNicola; Yoshitaka Shibata; Malikiya Hinds; Bjorg Gudmundsdottir; Juan J Haro-Mora; Selami Demirci; John F Tisdale
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-03       Impact factor: 6.698

8.  Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models.

Authors:  Naoya Uchida; Linhong Li; Tina Nassehi; Claire M Drysdale; Morgan Yapundich; Jackson Gamer; Juan J Haro-Mora; Selami Demirci; Alexis Leonard; Aylin C Bonifacino; Allen E Krouse; N Seth Linde; Cornell Allen; Madhusudan V Peshwa; Suk See De Ravin; Robert E Donahue; Harry L Malech; John F Tisdale
Journal:  Cell Rep Med       Date:  2021-04-20

Review 9.  Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors:  Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

10.  CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.

Authors:  Jennifer E Chung; Wendy Magis; Jonathan Vu; Seok-Jin Heo; Kirmo Wartiovaara; Mark C Walters; Ryo Kurita; Yukio Nakamura; Dario Boffelli; David I K Martin; Jacob E Corn; Mark A DeWitt
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.